URGN UroGen Pharma Ltd.

8-K Current Report

Filed: March 2, 2026

Health Care

Pharmaceutical Preparations

UroGen Pharma Ltd. (URGN) 8-K current report filed with SEC EDGAR on March 2, 2026. This page provides AI-powered analysis of reported events and material disclosures, including results of operations, corporate governance changes, agreements, and other triggering events as disclosed under Form 8-K item codes.

Reported 8-K Items
2 items

Item 1.01: Entry into a Material Definitive Agreement
Item 2.03: Creation of a Direct Financial Obligation

AI Filing Analysis
8-K

Item 1.01 · Entry into a Material Definitive Agreement

• Filing signed March 2, 2026 by CFO Chris Degnan, confirming authorized execution of material agreement disclosure
• No deal terms, counterparty, or financial obligations disclosed in this section — full agreement details likely in attached exhibit

Item 2.03 · Creation of a Direct Financial Obligation

• Item 2.03 signals a new financial obligation (loan, credit facility, or guarantee) that increases UroGen's debt load or contingent liabilities
• No terms disclosed in provided text — full details likely in an accompanying exhibit or cross-referenced section

Other UroGen Pharma Ltd. 8-K Filings

8-K Mar 2, 2026

Get deeper insights on UroGen Pharma Ltd.

Access full AI analysis, insider trading data, fund holdings, and cross-signal detection on SignalX.